Vera Therapeutics, Inc.

NasdaqGM:VERA Stock Report

Market Cap: US$2.9b

Vera Therapeutics Management

Management criteria checks 4/4

Vera Therapeutics' CEO is Marshall Fordyce, appointed in May 2016, has a tenure of 8.5 years. total yearly compensation is $3.43M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth $10.49M. The average tenure of the management team and the board of directors is 2.8 years and 4.1 years respectively.

Key information

Marshall Fordyce

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage17.1%
CEO tenure8.5yrs
CEO ownership0.4%
Management average tenure2.8yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Oct 07
Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 04

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Jul 22

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Jul 05
Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Jan 25

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Sep 06

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Aug 10

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16
Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25
We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

CEO Compensation Analysis

How has Marshall Fordyce's remuneration changed compared to Vera Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$134m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$3mUS$586k

-US$96m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$107m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$551k

-US$89m

Sep 30 2022n/an/a

-US$73m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$45m

Dec 31 2021US$1mUS$479k

-US$33m

Sep 30 2021n/an/a

-US$59m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$360k

-US$53m

Compensation vs Market: Marshall's total compensation ($USD3.43M) is below average for companies of similar size in the US market ($USD6.57M).

Compensation vs Earnings: Marshall's compensation has been consistent with company performance over the past year.


CEO

Marshall Fordyce (49 yo)

8.5yrs

Tenure

US$3,429,733

Compensation

Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...


Leadership Team

NamePositionTenureCompensationOwnership
Marshall Fordyce
Founder8.5yrsUS$3.43m0.36%
$ 10.5m
Sean Grant
Chief Financial Officer3.3yrsUS$1.76m0.036%
$ 1.0m
David Johnson
Chief Opearating Officerless than a yearno datano data
Joseph Young
Senior VP of Finance & Chief Accounting Officer3.5yrsno data0.031%
$ 884.5k
Jason Carter
Chief Legal Officerno datano datano data
Kelly Rauber
Senior Vice President of Human Resources2.8yrsno datano data
Tom Doan
Senior Vice President of Development Operations4.7yrsno datano data
Lauren Frenz
Chief Business Officer7.3yrsno datano data
Julien Capers
Senior Vice President of Legalno datano datano data
Neeraj Pakala
Senior VP and Head of Product Development & Manufacturing1.9yrsno datano data
Kerry Cooper
Senior Vice President of Medical Affairs1.5yrsno datano data
Robert Brenner
Chief Medical Officerless than a yearno datano data

2.8yrs

Average Tenure

50yo

Average Age

Experienced Management: VERA's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Marshall Fordyce
Founder8.5yrsUS$3.43m0.36%
$ 10.5m
Maha Katabi
Independent Director4.1yrsUS$153.63k0%
$ 0
Michael Morrissey
Independent Chairman of the Board2.5yrsUS$187.13k0%
$ 0
Patrick Gerald Enright
Independent Director4.1yrsUS$155.63k0%
$ 0
Beth Seidenberg
Independent Director8.4yrsUS$153.13k0.21%
$ 6.2m
Scott William Morrison
Independent Director4.6yrsUS$160.63k0%
$ 0
Andrew Cheng
Independent Director7.5yrsUS$154.63k0.028%
$ 800.2k
Christy Oliger
Directorless than a yearno data0.0047%
$ 136.7k
Kimball Hall
Independent Director2.9yrsUS$152.04k0%
$ 0

4.1yrs

Average Tenure

57yo

Average Age

Experienced Board: VERA's board of directors are considered experienced (4.1 years average tenure).